Vaxcyte (NASDAQ:PCVX) Releases Earnings Results, Beats Expectations By $0.27 EPS

Vaxcyte (NASDAQ:PCVX) posted its earnings results on Tuesday. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27, Briefing.com reports. During the same period last year, the firm earned ($0.91) EPS.

Vaxcyte Stock Down 1.3 %

NASDAQ PCVX traded down $1.37 on Thursday, reaching $102.70. The stock had a trading volume of 1,300,292 shares, compared to its average volume of 839,856. The firm has a market capitalization of $11.46 billion, a price-to-earnings ratio of -22.37 and a beta of 1.01. Vaxcyte has a 12-month low of $46.16 and a 12-month high of $121.06. The stock has a fifty day moving average price of $110.57 and a two-hundred day moving average price of $86.81.

Analyst Ratings Changes

PCVX has been the topic of a number of analyst reports. Mizuho raised their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Wednesday. Jefferies Financial Group lifted their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Bank of America boosted their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Finally, BTIG Research boosted their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $147.50.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now owns 478,888 shares in the company, valued at $37,822,574.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at approximately $21,968,226. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at $37,822,574.24. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 115,098 shares of company stock valued at $12,394,473 over the last quarter. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.